অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 25 mg - capsule - excipient ingredients: iron oxide red; iron oxide yellow; titanium dioxide; gelatin; iron oxide black; maize starch; pregelatinised maize starch; purified talc - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 150 mg - capsule - excipient ingredients: maize starch; gelatin; titanium dioxide; pregelatinised maize starch; purified talc - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pregabalin, quantity: 75 mg - capsule - excipient ingredients: pregelatinised maize starch; iron oxide red; gelatin; titanium dioxide; purified talc; iron oxide yellow; maize starch - pregabalin sandoz is indicated for the treatment of neuropathic pain in adults. pregabalin sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose; povidone; citric acid monohydrate; sodium hydroxide; macrogol poly(vinyl alcohol) grafted polymer; magnesium stearate; meglumine; colloidal anhydrous silica; lactose monohydrate; crospovidone - telmisartan/hct sandoz? is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 25 mg; telmisartan, quantity: 80 mg - tablet, film coated - excipient ingredients: meglumine; sodium hydroxide; citric acid monohydrate; lactose; macrogol poly(vinyl alcohol) grafted polymer; povidone; magnesium stearate; colloidal anhydrous silica; iron oxide yellow; lactose monohydrate; crospovidone - telmisartan/hct sandoz? is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, film coated - excipient ingredients: iron oxide red; povidone; meglumine; magnesium stearate; sodium hydroxide; lactose; iron oxide yellow; macrogol poly(vinyl alcohol) grafted polymer; citric acid monohydrate; colloidal anhydrous silica; lactose monohydrate; crospovidone - telmisartan/hct sandoz? is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol; polysorbate 80; citric acid; nitrogen - docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel sandoz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel sandoz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel sandoz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel sandoz in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of =1cm and < 7cm. docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. docetaxel sandoz is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy. docetaxel sandoz is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. docetaxel sandoz, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol; nitrogen - docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel sandoz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel sandoz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel sandoz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel sandoz in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of =1cm and < 7cm. docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. docetaxel sandoz is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy. docetaxel sandoz is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. docetaxel sandoz, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.